Evidence map›Paper›PMID 35071525›Full record

ArticleWorld journal of clinical cases2022

Successful response to camrelizumab in metastatic bladder cancer: A case report.

Chen Xie, Xia Yuan, Shu-Hui Chen, Zhi-Yong Liu, Di-La Lu, Feng Xu, Zhi-Qiu Chen, Xiao-Ming Zhong

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chen XieDepartment of Radiotherapy, Jiangxi Provincial Tumour Hospital, Nanchang 330029, Jiangxi Province, China.
Xia YuanDepartment of Radiotherapy, Jiangxi Provincial Tumour Hospital, Nanchang 330029, Jiangxi Province, China.
Shu-Hui ChenDepartment of Radiotherapy, Jiangxi Provincial Tumour Hospital, Nanchang 330029, Jiangxi Province, China.
Zhi-Yong LiuDepartment of Radiotherapy, Jiangxi Provincial Tumour Hospital, Nanchang 330029, Jiangxi Province, China.
Di-La LuDepartment of Radiotherapy, Jiangxi Provincial Tumour Hospital, Nanchang 330029, Jiangxi Province, China.
Feng XuFaculty of Medicine, Burning Rock Biotech, Guangzhou 510300, Guangdong Province, China.
Zhi-Qiu ChenFaculty of Medicine, Burning Rock Biotech, Guangzhou 510300, Guangdong Province, China.
Xiao-Ming ZhongDepartment of Radiotherapy, Jiangxi Provincial Tumour Hospital, Nanchang 330029, Jiangxi Province, China.
Jiangxi Provincial Cancer Hospital · CNBurning Rock Biotech (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere has been no report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive programmed death-ligand 1 (PD-L1) expression and high tumor mutational burden (TMB). More effective predictors of bladder cancer immunotherapy have yet to be explored, and the combination of multiple factors may be more predictive than a single factor. CASE SUMMARY: We report the case of a 74-year-old male patient with recurrent metastatic bladder cancer, which demonstrated positive PD-L1 expression and high TMB. The immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin. The patient achieved a partial response with a progression-free survival of 11 mo.

conclusionThis is the first report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive PD-L1 expression and high TMB.

Indexed as

Bladder cancerCamrelizumabCase reportNext-generation sequencingProgrammed death-ligand 1Tumor mutational burden

Identifiers

PMID35071525
PMCPMC8727277
OpenAlexW4200338861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.